Aims and objectives
Prostate cancer (PCa) is the second most common cancer in men worldwide [1,2]; it is a heterogeneous disease that ranges clinically from indolent to highly aggressive.
The prevalence of prostate cancer increases with age; 34% of men in the 5th decade of life and up to 70% aged 80 years or older have histologic evidence of prostate cancer.
Sixteen percent of males will develop prostate cancer during their lifetime [3-5],
but only a small proportion of those patients will die because of PCa.
Multiparametric Magnetic...
Methods and materials
Patients
We analyzed the images of 343men who underwent prostate MRI examinations in our institution between May 2016 and May2017.
Patients who met the following inclusion criteria were selected: (a) 1.5-Tesla MRI of the prostate,
including a DWI sequence with b 50,
600,
1000 and 1400 sec/ mm2,
(b) increased PSA level (>4 ng/ml) (b) TRUS-guided biopsies performed at our institution within 6 months after MRI.
Exclusion criteria were: (a) previous prostate cancer treatment,
including hormone therapy or radiation; (b) incomplete imaging protocol; (c) TRUS-guided...
Results
Ninety patients (mean age 58 years,
range 48-78) with increased PSA level (mean 8.0 ng/ml,
range 4.0-36)were retrospectively studied aftermpMRI and TRUS-guided biopsies.
Among the 41/90 patients with negative MRI for clinically significant PCa,35/41 were negative at histopathological results after TRUS-guided biopsies (Fig.1).
Only 4 patients had negative MRI with clinically significant PCaafter TRUS-guided biopsies (3 Gleason score [GS] 3+4; 1 GS 4+3).
Among the 49/90 patients with positive MRI for clinically significant PCa,
35/49 were positive at histopathologic results after TRUS-guided biopsies (Fig.
2)....
Conclusion
Multiparametric MRI has a good NPV and could be a potential tool in excluding clinically significant PCa in comparison with histopathological results after TRUS-guidedbiopsies in patients with increased PSA level and may provide valuable additional information in patient’s managementto rule out clinically significant prostate cancer before biopsy.
Personal information
E.
Demozzi,
MD
Sacro Cuore Don Calabria Hospital; Department of Radiology- Negrar,
Verona (VR) - Italy.
Via Don A.
Sempreboni,
5
37024 Negrar,
Verona (VR),
Italy
Phone: + 39 045 601 3111
Fax: +39 045 750 0480
e-mail:
[email protected]
References
1.
World Cancer Research Fund International/American Institute for Cancer Research Continous Update Project: Diet,
Nutrition,
Physical Activity,
and Prostate Cancer.
2014.
www.wcrf.org/site/default/files/Prostate-Cancer-2014-Report.pdf.
Accessed 1 Dec 2015
2.
Jemal.
American Cancer Society.
Prostate cancer facts.
In: Cancer facts & figures 2009.
Atlanta,
Ga: American Cancer Society 2009;19-20
3.
American Cancer Society.
Prostate cancer facts.
In: Cancer facts & figures 2009.
Atlanta,
Ga: American Cancer Society,
2009;19-2
4.
Chan JM et al.
The relative impact and future burden of prostate cancer in the United States.
J Urol...